1. Home
  2. CYRX
  3. Earnings

AI Earnings Predictions for CryoPort Inc. (CYRX)

Machine learning predictions based on historical earnings data and price patterns

Latest Prediction

BUY

1-Day Prediction

+5.82%

$17.67

100% positive prob.

5-Day Prediction

+12.14%

$18.73

100% positive prob.

20-Day Prediction

+11.55%

$18.63

95% positive prob.

Price at prediction: $16.70 Confidence: 100.0% Model AUC: 1.0000 Quarter: Q3 2026

Historical Earnings Predictions

Quarter Signal 1D Return 5D Return 20D Return Confidence Actual 5D
Q3 2026 BUY +5.82% +12.14% +11.55% 100.0% Pending
Q2 2026 SELL -5.62% -8.00% -9.82% 100.0% Pending
Q1 2026 BUY +4.77% +11.39% +7.68% 100.0% +28.99%
Q4 2025 SELL -6.75% -7.52% -10.40% 84.2% -7.18%

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K BUY

Nov 5, 2026 · 100% conf.

AI Prediction BUY

1D

+5.82%

$17.67

Act: +18.47%

5D

+12.14%

$18.73

20D

+11.55%

$18.63

Price: $16.70 Prob +5D: 100% AUC: 1.000
0001104659-26-123381

EX-99.1

2 tm2629096d1_ex99-1.htm

EXHIBIT 99.1

Exhibit 99.1

Cryoport Reports Third Quarter 2026 Financial Results

·Third quarter revenue grew 14% year-over-year to $50.2 million

·Commercial Cell and Gene Therapy revenue increased 20% year-over-year

·Supporting a record 788 global clinical trials and 23 commercially approved cell and gene therapies as of September 30, 2026

·Raises full-year 2026 revenue guidance to $197 million - $199 million

NASHVILLE,

Tennessee, November 5, 2026, - Cryoport, Inc. (NASDAQ: CYRX) (“Cryoport” or the “Company”), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its third quarter (Q3) and first nine months (9M) of 2026.

Jerrell Shelton, CEO of Cryoport, stated, “Cryoport delivered third quarter revenue of $50.2 million, reflecting continued momentum across our core cell and gene therapy (CGT) business. Revenue from commercial CGT clients increased 20% year over year, BioStorage/BioServices revenue expanded 25%, and total Life Sciences Services revenue grew 18%, underscoring the strength of our integrated platform and the growing demand for our solutions. These results reflect both the increasing number of patients worldwide receiving CGT treatments and the continued adoption of our end-to-end temperature-controlled supply chain solutions. We also achieved 8% year over year growth in Life Sciences Products revenue, supported by MVE Biological Solutions’ (MVE) position as the global market leader in cryogenic systems.”

“During the quarter, we further strengthened our leadership position within the CGT ecosystem, ending the period supporting 23 commercial therapies and a record of 788 clinical trials worldwide. Our integrated platform, disciplined execution, and growing utilization of our Global Supply Chain Center Network continue to enhance scalability and operating leverage, advancing our progress toward sustained profitability. This momentum was reflected in our positive adjusted EBITDA of $1.1 million for the quarter, representing another important milestone in our pathway to profitability initiative.

“Our strong year-to-date performance, combined with expanding support of commercial therapies, deepening customer relationships, a robust clinical trial pipeline, and continued demand for MVE’s industry-leading products, gives us confidence in our outlook. As a result, we are increasing our full-year 2026 revenue guidance to a range of $197 million to $199 million,” concluded Mr. Shelton.

1

The following table presents Q3 2026 revenue compared with Q3 2025:

Cryoport, Inc. and Subsidiaries

Revenue

Three Months Ended September 30, (unaudited) Nine Months Ended September 30, (unaudited)

(in thousands) 2026 2025 % Change 2026 2025 % Change

Life Sciences Services $28,564 $24,258 18% $83,431 $71,492 17%

BioLogistics Solutions 22,522 19,428 16% 66,549 57,832 15%

BioStorage/BioServices 6,042 4,830 25% 16,882 13,660 24%

Life Sciences Products $21,656 $19,975 8% $63,558 $59,235 7%

Total Revenue $50,220 $44,233 14% $146,989 $130,727 12%

BioLogistics Solutions revenue increased 16% year-over-year in Q3 2026, driven by continued commercial therapies development, and clinical trial progress within the CGT market. BioStorage/BioServices revenue grew 25% year-over-year, reflecting another strong quarter of demand for our expanded, integrated services offering, which provides seamless, secure handling of temperature-sensitive materials across our global network.

As of September 30, 2026, the number of commercial cell and gene therapies we support increased to 23 and our total global clinical trial count that we support rose to 788 clinical trials, a net increase of 43 clinical trials over September 30, 2025, with 99 of these clinical trials in Phase 3. The number of trials by phase and region are as follows:

Cryoport Supported Clinical Trials by Phase

September 30,

Clinical Trials 2024 2025 2026

Phase 1 295 309 319

Phase 2 317 353 370

Phase 3 79 83 99

Total 691 745 788

Cryoport Supported Clinical Trials by Region

September 30,

Clinical Trials 2024 2025 2026

Americas 531 559 589

EMEA

112 137 143

APAC

48 49 56

Total 691 745 788

In Q3 2026, Cryoport’s customer, Replimune, received accelerated U.S. Food and Drug Administration (FDA) approval for TUDRIQEV™ for the treatment of adults with unresectable advanced cutaneous melanoma, a skin cancer that has spread too widely or deeply to be safely or completely removed with surgery. Also, during the quarter Crispr Therapeutics and their partner Vertex Pharmaceuticals received FDA supplemental approval to expand the label of CASGEVY® for treatment of people 2 years of age and older with either Sickle Cell Disease (SCD) or Transfusion-dependent Beta Thalassemia (TDT). CASGEVY is the first approved genetic therapy indicated for children as young as 2 years for both SCD and TDT .

2

Two of Cryoport’s customers filed Biologics

2026
Q2

Q2 2026 Earnings

8-K SELL

Aug 6, 2026 · 100% conf.

AI Prediction SELL

1D

-5.62%

$13.88

Act: +2.79%

5D

-8.00%

$13.53

20D

-9.82%

$13.27

Price: $14.71 Prob +5D: 0% AUC: 1.000
0001104659-26-092064

EX-99.1

2 tm2622464d1_ex99-1.htm

EXHIBIT 99.1

Exhibit 99.1

Cryoport Reports Second Quarter 2026 Financial Results

·Second quarter revenue grew 8% year-over-year to $49.0 million

·Life Sciences Services revenue increased 15% year-over-year

·BioStorage/BioServices revenue grew 25% year-over-year

·Supporting 779 global clinical trials and 22 commercially approved cell and gene therapies (CGT) as of June 30, 2026

NASHVILLE,

Tennessee, August 6, 2026, - Cryoport, Inc. (NASDAQ: CYRX) (“Cryoport” or the “Company”), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its second quarter (Q2) and first half (H1) of 2026.

Jerrell Shelton, CEO of Cryoport, commented, “Our revenue momentum over the past several periods continued into the second quarter, with total revenue reaching $49.0 million. Life Sciences Services revenue grew 15% year-over-year, led by 25% growth in BioStorage/BioServices revenue. Our Life Sciences Products business also generated solid results during the quarter, driven by continued demand for MVE Biological Solutions’ industry-leading cryogenic systems and the successful introduction of new and innovative products.

“Total revenue from the support of commercial CGT grew 9% year-over-year to $9.4 million. The Life Science Services portion of our revenue from supporting commercial CGT grew 26% year-over-year as the number of patients treated in the community setting and on an outpatient basis continued to ramp. Total revenue for the quarter from supporting CGT clinical trials increased 12% year-over-year to $13.4 million as our customers’ clinical pipelines advanced and further matured. We supported a record 779 clinical trials globally as of June 30, 2026, reflecting the strength of our industry-leading position as the CGT market continues to advance.

“Our second quarter results also reflect meaningful progress on our “pathway to profitability.” Achieving positive adjusted EBITDA in the second quarter represents an important milestone in our ongoing pathway to sustainable profitability and demonstrates the value of our strategic investments and operational initiatives we have executed over the past several years. We are pleased with this accomplishment as we continue to optimize our global operations, leverage our expanding infrastructure, and benefit from the operating leverage that we anticipate will take effect as we increasingly scale and put our investments to work.

1

“Overall, we delivered a strong second quarter, generating growth across key revenue streams, improving profitability, and achieving an important milestone with positive adjusted EBITDA for the quarter. With our accomplishments to date, we believe that we are well positioned to further expand margins, enhance operating efficiency, and deliver sustainable, profitable long-term growth for our shareholders. We remain focused on executing our strategy, driving financial performance, and capitalizing on the significant opportunities before us. We expect upcoming growth catalysts in our business segments, represented by the expansion of our Global Supply Chain Center Network and recent launches of new products and services, will drive us to new heights in market position, growth, and productivity,” concluded Mr. Shelton.

The following table presents Q2 2026 revenue compared with

Q2 2025:

Cryoport, Inc. and Subsidiaries

Revenue

Three Months Ended June 30, (unaudited) Six Months Ended June 30, (unaudited)

(in thousands) 2026 2025 % Change 2026 2025 % Change

Life Sciences Services $27,969 $24,369 15% $54,867 $47,234 16%

BioLogistics Solutions 22,359 19,874 13% 44,027 38,404 15%

BioStorage/BioServices 5,610 4,495 25% 10,840 8,830 23%

Life Sciences Products $21,002 $21,085 0% $41,902 $39,260 7%

Total Revenue $48,971 $45,454 8% $96,769 $86,494 12%

BioLogistics Solutions revenue increased 13% year-over-year in Q2 2026, driven by increasing customer activity, continued commercial product development, and clinical advancement within the CGT market. BioStorage/BioServices revenue grew 25% year-over-year, reflecting strong demand for our expanded, integrated services offering, which provides seamless, secure handling of temperature-sensitive materials across our global network.

As of June 30, 2026, the number of commercial cell and gene therapies we support increased to 22 and our total clinical trial count that we support rose to 779 clinical trials worldwide, a net increase of 51 clinical trials over June 30, 2025, with 94 of these clinical trials in Phase 3. The number of trials by phase and region are as follows:

2

Cryoport Supported Clinical Trials by Phase

June 30,

Clinical Trials 2024 2025 2026

Phase 1 286 304 316

Phase 2 322 342 369

Phase 3 76 82 94

Total 684 728 779

Cryoport Supported Clinical Trials by Region

June 30,

Clinical Trials 2024 2025 2026

Americas 525 556 579

EMEA

114 124 145

APAC

45 48 55

Total

2026
Q1

Q1 2026 Earnings

8-K BUY

May 4, 2026 · 100% conf.

AI Prediction BUY

1D

+4.77%

$10.70

Act: +19.39%

5D

+11.39%

$11.37

Act: +28.99%

20D

+7.68%

$10.99

Act: +54.16%

Price: $10.21 Prob +5D: 100% AUC: 1.000
0001104659-26-054942

EX-99.1

2 tm2613494d1_ex99-1.htm

EXHIBIT 99.1

Exhibit 99.1

Cryoport Reports First Quarter 2026 Financial Results

●First quarter revenue grew 16% year-over-year to $47.8 million

●Commercial cell and gene therapy (CGT) revenue grew 26% year-over-year to $9.1 million, reflecting continued expansion in approved CGT programs

●Life Sciences Services revenue increased 18% year-over-year, led by 21% growth in BioStorage/BioServices

●Life Sciences Products revenue increased 15% year-over-year, driven by strong demand for cryogenic systems

●Supporting a record 766 global clinical trials and 21 commercially approved CGTs as of March 31, 2026

●Company raises full-year revenue guidance to $192 million - $196 million

NASHVILLE,

Tennessee, May 4, 2026, - Cryoport, Inc. (NASDAQ: CYRX) (“Cryoport” or the “Company”), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its first quarter (Q1) of 2026.

Jerrell Shelton, CEO of Cryoport, commented, “Cryoport delivered a strong start to 2026 with first-quarter revenue of $47.8 million, up 16% year-over-year, reflecting a continuation of our momentum over the past several quarters across our integrated services and products platform. Revenue in support of commercial Cell and Gene Therapies (CGT) grew 26% to $9.1 million, while clinical trial support revenue grew 18% to $12.9 million. We continue to support one of the industry’s broadest CGT pipelines, and our leadership across both clinical and commercial programs positions us well for sustainable growth.

“Our Life Sciences Services segment delivered another strong quarter, with revenue increasing 18% year-over-year, including 21% growth in BioStorage/BioServices. This performance reflects the increasing scope and complexity of the Cell & Gene Therapy programs we support and underscores the critical role we play in supporting our clients with our integrated, temperature-controlled supply chain services.

“Our Life Sciences Products segment also performed very well, generating 15% revenue growth, driven by global demand for MVE Biological Solutions’ cryogenic systems. MVE continues to innovate and further solidify its position as the global leader in high-quality cryogenic systems.

1

“This growth across both our reporting segments, combined with solid gross margins and continued operational discipline, drove a $2.2 million year-over-year improvement in adjusted EBITDA from continuing operations, advancing us meaningfully along our “pathway to profitability.”

“Looking ahead, we see multiple growth catalysts extending beyond 2026, including the planned launch of BioServices operations at our Global Supply Chain Center in Paris, France in the third quarter, and the planned opening of our new Global Supply Chain Center in Santa Ana, California in the fourth quarter. These strategic investments expand our global footprint in key geographies and further strengthen our ability to support the advancement and commercialization of life-saving therapies globally. Reflecting on our strong performance in the first quarter and increased visibility into the remainder of the year, we are raising our full-year revenue guidance to $192 million to $196 million,” concluded Mr. Shelton.

The following table presents Q1 2026 revenue compared with Q1 2025:

Cryoport, Inc. and Subsidiaries

Revenue

Three Months Ended March 31, (unaudited)

(in thousands) 2026 2025 % Change

Life Sciences Services $26,898 $22,865 18%

BioLogistics Solutions 21,668 18,531 17%

BioStorage/BioServices 5,230 4,334 21%

Life Sciences Products $20,900 $18,175 15%

Total Revenue $47,798 $41,040 16%

BioLogistics Solutions revenue increased 17% year-over-year in Q1 2026, driven by increasing customer activity, continued commercial product maturation, and clinical advancement within the CGT market. BioStorage/BioServices revenue grew 21% year-over-year, reflecting strong demand for our expanded, integrated services offering, which provides seamless, secure handling of temperature-sensitive materials across our global network.

Revenue from the support of commercial CGTs increased 26% year-over-year to $9.1 million and as of March 31, 2026, the number of commercial therapies we support increased to 21.

2

As of March 31, 2026, Cryoport supported a total of 766 global clinical trials, a net increase of 55 clinical trials over March 31, 2025, with 91 of these clinical trials in Phase 3. The number of trials by phase and region are as follows:

Cryoport Supported Clinical Trials by Phase

March 31,

Clinical Trials 2024 2025 2026

Phase 1 286 304 318

Phase 2 312 328 357

Phase 3 77 79 91

Total 675 711 766

Cryoport Supported Clinical Trials by Region

March 31,

Clinical Trials 2024 2025 2026

Americas 518 544 569

EMEA

112 118 143

APAC

45 49 54

Total 675 711 766

In Q1 2026, four Biologics License Applications (BLA) / Marketing Authorization Applications (MAA) filings occu

About CryoPort Inc. (CYRX) Earnings

This page provides CryoPort Inc. (CYRX) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.

Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on CYRX's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.

Share on Social Networks: